<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV) is an oncogenic virus associated with a number of human <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> including Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp>, <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative disease</z:e> and, though still debated, <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>A subset of latent EBV antigens is required for mediating immortalization of primary B-lymphocytes </plain></SENT>
<SENT sid="2" pm="."><plain>Here we demonstrate that the carboxy-terminal region of the essential latent antigen, EBNA-3C, interacts specifically with the human metastatic suppressor protein Nm23-H1 </plain></SENT>
<SENT sid="3" pm="."><plain>Moreover, EBNA-3C reverses the ability of Nm23-H1 to suppress the migration of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells and <z:hpo ids='HP_0003002'>breast carcinoma</z:hpo> cells </plain></SENT>
<SENT sid="4" pm="."><plain>We propose that EBNA-3C contributes to EBV-associated human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> by targeting and altering the role of the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> suppressor Nm23-H1 </plain></SENT>
</text></document>